ArticleBMC medical research methodology2019
Incidence of advanced colorectal cancer in Germany: comparing claims data and cancer registry data.
Article in BMC medical research methodology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of methods to estimate colorectal cancer incidence using population-based cancer registries.BMC medical research methodology · 2022Pooled it
- Statistical methods for measuring trends in colorectal cancer incidence in registries: A systematic review.Frontiers in oncology · 2022Pooled it
- Do ethnic disparities exist in disease burden and healthcare utilization of male breast cancer? A 9-year cohort study of 9.08 million adults in China.Journal of the National Cancer Center · 2025Article
- Assigning cancer stage to patients using administrative claims data: an example for colon and rectal cancers.BMC health services research · 2025Article
- Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017.Cancer medicine · 2025Article
- Exploring the potential of German claims data to identify incident lung cancer patients.BMC pulmonary medicine · 2025Article
- Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany.Cancer reports (Hoboken, N.J.) · 2024Article
- Proportion and characteristics of screen-detected and non-screen-detected colo-rectal cancers in Germany.Acta oncologica (Stockholm, Sweden) · 2024Article
- Age differences in the treatment of lung cancer-a cohort study among 42,000 patients from Germany.Journal of cancer research and clinical oncology · 2024Article
- A comparative examination of colorectal cancer burden in European Union, 1990-2019: Estimates from Global Burden of Disease 2019 Study.International journal of clinical oncology · 2022Article
- Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery-an analysis of German claims data.BMC cancer · 2022Article
- The HROC-Xenobank-A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models.Cancers · 2021Article
- Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries.Frontiers in oncology · 2021Article
- Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease.Deutsches Arzteblatt international · 2020Article
- The Validity of Registered Synchronous Peritoneal Metastases from Colorectal Cancer in the Danish Medical Registries.Clinical epidemiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncidence rates of advanced cancer stages are important, e.g., for monitoring cancer screening programs. However, information from cancer registries on tumor stage is often incomplete. Exemplified by colorectal cancer (CRC), we explored the potential of German claims data to estimate incidence rates of advanced cancer stages.
methodsWe used claims data of the German Pharmacoepidemiological Research Database (GePaRD; information on > 20 million persons) to identify incident patients with advanced CRC based on ICD-10 codes for CRC and secondary malignant neoplasms. We calculated annual age-standardized incidence rates (ASIRs) of advanced CRC per 100,000 for the years 2008-2015 stratified by the presence of affected lymph nodes only (C77) vs. distant metastases (C78-C79) and compared them to ASIRs determined using data (2008-2014) from the German Centre for Cancer Registry Data (ZfKD).
resultsIn GePaRD, the ASIRs of advanced CRC per 100,000 in 2014 were 21.5 among men and 14.9 among women. Compared to ZfKD data the ASIR in GePaRD was 2.58 lower in men and 0.27 higher in women (per 100,000) in 2014. Stratification by presence of distant metastases showed divergent patterns: the ASIRs regarding distant metastases were ~ 50% (women) and ~ 30% (men) higher, and the ASIRs regarding affected lymph nodes only were ~ 40% lower in GePaRD as compared to ZfKD.
conclusionWhile ASIRs of advanced CRCs overall agreed well between claims and cancer registry data in 2014, the analyses stratified by presence of distant metastases showed differences. Cancer registries might underestimate ASIRs of CRCs with distant metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.